Latest news and press releases about CRISPR Therapeutics AG (CRSP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Price
| Price | $52.21 |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 2.86 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -1534.39% |
| Operating Margin | -3971.53% |
| Net Margin | -3368.72% |
Related companies: ACLX · AKRO · ARWR · CYTK · KRYS · MTSR · NUVL
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks